Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of the Radiative Decay D_{s0}^{*}(2317)^{+}→D_{s}^{*+}γ.

Physical review letters·2026
Same author

First Search for B→X_{s}νν[over ¯] Decays.

Physical review letters·2026
Same author

Search for Feebly Interacting Particles in B Decays with Missing Energy at Belle.

Physical review letters·2026
Same author

Using kidney transplantation to explore epigenetic markers of frailty.

GeroScience·2026
Same author

Investigating solid-fluid phase coexistence in dc plasma bilayer crystals: The role of particle pairing and mode coupling.

Physical review. E·2026
Same author

The Coffee was Paid for Dearly: Shipwreck BZN4 and the Frigate<i>'t Hart</i>.

Journal of maritime archaeology·2025
Same journal

Foreign Body Migration from Subglottis to Bronchus in a Tracheostomised Child: A Case Report.

JNMA; journal of the Nepal Medical Association·2026
Same journal

Validation of the Nepalese Version of the Quality of Recovery-15 Questionnaire in Patients Undergoing Elective Surgery.

JNMA; journal of the Nepal Medical Association·2026
Same journal

Evaluation of Preference of Pain Scale in Children using Novel Animated Emoji Scale in Nepal: An Observational Study.

JNMA; journal of the Nepal Medical Association·2026
Same journal

Mucinous Ovarian Cancer in a Young Woman: A Case Report.

JNMA; journal of the Nepal Medical Association·2026
Same journal

Conundrum of Cholesterol Management and Health Implications of Low Cholesterol Levels: A Narrative Review.

JNMA; journal of the Nepal Medical Association·2026
Same journal

Clinical Profile and Management of Pleural Effusion at Tertiary Hospital of Nepal: An Observational Study.

JNMA; journal of the Nepal Medical Association·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Repaglinide induced acute hepototoxicity.

S Jaiswal1, R Mehta, M Musuku

  • 1Department of Medicine, Mercy Catholic Medical Center, Drexel University College of Medicine, Philadelphia, USA. sjkalu@gmail.com

JNMA; Journal of the Nepal Medical Association
|April 15, 2010
PubMed
Summary
This summary is machine-generated.

Repaglinide is generally safe, but rare cases of liver damage can occur. This case report details acute hepatotoxicity in an elderly woman using repaglinide.

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Published on: April 16, 2019

Related Experiment Videos

Last Updated: Jun 13, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Published on: April 16, 2019

Area of Science:

  • Pharmacology
  • Hepatology
  • Internal Medicine

Background:

  • Repaglinide is an oral hypoglycemic agent used for type 2 diabetes.
  • Common side effects include hypoglycemia, headache, and gastrointestinal issues.
  • Elevated liver enzymes are a rare, documented adverse event.

Observation:

  • A case report of acute hepatotoxicity is presented.
  • The patient was a 78-year-old woman.
  • Hepatotoxicity developed during repaglinide therapy.

Findings:

  • The patient experienced acute hepatotoxicity.
  • This represents a rare adverse event associated with repaglinide use.
  • The severity and mechanism of repaglinide-induced hepatotoxicity require further investigation.

Implications:

  • Clinicians should be aware of the potential for rare hepatotoxicity with repaglinide.
  • Monitoring liver function may be warranted in patients on repaglinide, especially those with risk factors.
  • Further research is needed to understand the pathophysiology and incidence of this rare side effect.